


MASH Drugs Market Set to Hit \$929M by 2033 Amid New Approvals and Innovative Therapies

Global MASH drugs market grows rapidly, fueled by new FDA approvals, innovative pipeline therapies, and rising obesity-driven demand.

LOS ANGELES, CA, UNITED STATES, October 24, 2025 /EINPresswire.com/ -- The [Metabolic Dysfunction-Associated Steatohepatitis \(MASH\) Market](#) reached US\$ 180.1 million in 2024 and is projected to reach US\$ 929.05 million by 2033, growing at a CAGR of 18.1% during the forecast period 2025–2033.



Top Key Players – Akero, Boeringer Ingelhei, Novo Nordisk, Madrigal Pharmaceuticals.



The MASH market is entering a new era with FDA-approved therapies and promising pipeline drugs addressing liver fibrosis and metabolic dysfunction.”

DataM Intelligence

For more information, visit <https://www.datamintelligence.com/download-sample/metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market>

<https://www.datamintelligence.com/download-sample/metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market>

United States – Industry News

□ FDA Approves Wegovy for MASH

On August 18, 2025, the FDA approved Novo Nordisk’s Wegovy for treating noncirrhotic MASH, marking it as the

second FDA-approved drug for the condition.

□ FDA Accepts Surrogate Endpoint Proposal for MASH

On August 27, 2025, the FDA accepted a proposal for a surrogate endpoint in MASH trials, potentially expediting future drug approvals.

Japan – Industry News

□ Inventiva and Hepalys Initiate Phase 1 Trial

In February 2025, Inventiva and Hepalys Pharma began a Phase 1 clinical trial in Japan for lanifibranor, a pan-PPAR agonist targeting MASH.

South Korea – Industry News

□ South Korean Biotech's GLP-1 Drug Shows MASH Efficacy

On June 16, 2025, a South Korean biotech's GLP-1 candidate demonstrated reduced liver fat in MASH patients, with added weight loss benefits.

□ Dong-A ST and Hanmi Pharm Showcase MASH Drug

On June 23, 2025, Dong-A ST and Hanmi Pharmaceutical presented advancements in MASH treatments at a major event.

Europe – Industry News

□ EMA Grants Conditional Authorisation to Rezdiffra

On June 20, 2025, the European Medicines Agency recommended conditional authorisation for Madrigal Pharmaceuticals' Rezdiffra, the first MASH treatment in the EU.

□ EMA Qualifies AIM-NASH AI Tool for Liver Biopsy Analysis

On March 20, 2025, the EMA qualified AIM-NASH, an AI tool to assist pathologists in diagnosing MASH from liver biopsy samples.

Looking For A Detailed Full Report? Get it here: <https://www.datamintelligence.com/buy-now-page?report=metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market>

Key Drug Approvals

- Resmetirom (Rezdiffra): Approved in 2024, resmetirom is the first FDA-cleared treatment for MASH, targeting liver fat accumulation and inflammation.
- Wegovy (Semaglutide): In August 2025, Wegovy received accelerated FDA approval for MASH, becoming the first GLP-1 receptor agonist approved for this indication.
- Efruxifermin: Akero Therapeutics' efruxifermin has shown promising Phase 3 results, with significant improvements in liver fibrosis and cirrhosis symptoms.

Pipeline & Emerging Therapies

The MASH pipeline is robust, with several investigational therapies in various stages of development:

- Lanifibranor: An agonist of PPAR receptors, showing potential in reducing liver inflammation and fibrosis.
- Efruxifermin: A FGF21 analog demonstrating significant improvements in liver fibrosis and cirrhosis symptoms.
- GLP-1 Receptor Agonists: Drugs like Wegovy are being explored for their effects on liver fat reduction and metabolic improvements.

Market Segments:

- By Disease Stage (Intraoral X-ray, Extraoral X-ray, Imaging Software, Others)
- By Medication (2D Digital Radiography, 3D CBCT, Optical/impression scanners, Digital sensors,

Hybrid Systems)

- By Route of Administration (Endodontics, Implantology, Orthodontics, Oral & Maxillofacial Surgery, Others)

Get Customization in the report as per your requirements:

<https://www.datamintelligence.com/customize/metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market>

Growth Drivers:

- Rising Obesity Rates: Approximately 2.3 billion children and adults are living with overweight or obesity, creating a direct risk for MASH.
- Advancements in Drug Development: The approval of new therapies, such as resmetirom and Wegovy, is expanding treatment options.
- Increased Awareness: Growing recognition of MASH as a serious liver disease is driving demand for effective treatments.

Regional Insights:

- North America: Dominated the market with a revenue share of 43.5% in 2024.
- Asia-Pacific: Expected to witness the fastest growth during the forecast period, driven by increasing obesity rates and healthcare access

Related Reports:

[NASH/MASH Treatment Market](#)

[Melasma Treatment Market](#)

Kailas Disale

DataM Intelligence 4market Research LLP

+1 877-441-4866

kailas@datamintelligence.com

This press release can be viewed online at: <https://www.einpresswire.com/article/861172122>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.